Cargando…

The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region

OBJECTIVES: We report the incidence of tuberculosis (TB) across certolizumab pegol (CZP) clinical trials in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), before and after the introduction of stricter TB screening. METHODS: TB incidence rates (IR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mariette, X, Vencovsky, J, Lortholary, O, Gomez-Reino, J, de Longueville, M, Ralston, P, Weinblatt, M, van Vollenhoven, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613160/ https://www.ncbi.nlm.nih.gov/pubmed/26509064 http://dx.doi.org/10.1136/rmdopen-2014-000044

Ejemplares similares

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
por: Furst, D E, et al.
Publicado: (2015)

Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database
por: Clowse, Megan E. B., et al.
Publicado: (2018)

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials
por: Combe, Bernard, et al.
Publicado: (2016)

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
por: Curtis, Jeffrey R., et al.
Publicado: (2015)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
por: Glatt, Sophie, et al.
Publicado: (2019)

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study
por: Saraux, Alain, et al.
Publicado: (2020)

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
por: Bykerk, V P, et al.
Publicado: (2015)

Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
por: Schiff, Michael, et al.
Publicado: (2016)

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
por: Mease, P, et al.
Publicado: (2015)

Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2018)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
por: Fleischmann, Roy, et al.
Publicado: (2017)

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
por: Alten, Rieke, et al.
Publicado: (2017)

Meaning of patient global assessment when joint counts are low in rheumatoid arthritis
por: Felson, David, et al.
Publicado: (2022)

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial
por: van Vollenhoven, R. F., et al.
Publicado: (2015)

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA
por: Platten, Michael, et al.
Publicado: (2017)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
por: Weinblatt, Michael E, et al.
Publicado: (2013)

Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis
por: Scharbatke, Eva C., et al.
Publicado: (2016)

Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists
por: Lesuis, N, et al.
Publicado: (2016)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies
por: Fleischmann, Roy, et al.
Publicado: (2017)

Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial
por: Levitsky, Adrian, et al.
Publicado: (2017)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis
por: Ahmad, Harris A., et al.
Publicado: (2020)

Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week‐112 Efficacy and Safety Results of the Open‐Label Long‐Term Extension of a Phase III, Double‐Blind, Randomized, Placebo‐Controlled Trial
por: Bingham, Clifton O., et al.
Publicado: (2015)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Relationship Between Baseline and Early Changes in C‐Reactive Protein and Interleukin‐6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis
por: Wang, Jianmei, et al.
Publicado: (2016)

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2020)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate‐Treated Early Rheumatoid Arthritis Patients
por: Lourdudoss, Cecilia, et al.
Publicado: (2018)

Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months
por: Bykerk, Vivian P., et al.
Publicado: (2021)

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
por: Dikranian, Ara H, et al.
Publicado: (2022)

Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016)

Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre
por: Reuter, Katja, et al.
Publicado: (2022)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
por: van Vollenhoven, Ronald F., et al.
Publicado: (2018)

A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
por: Hambardzumyan, Karen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fegt6p7klopklmhbic856gtu87